Clinical Study of Selective Fecal Microbiota Transplantation in the Treatment of Irritable Bowel Syndrome.
17. mai 2021 oppdatert av: Yanling Wei
Clinical Comparative Study of Precision Flora Transplantation and Standardized Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome.
In order to seek a more precise and convenient treatment, we made a self-made precise transplant capsule that is effective against diarrhea.
Compared with standardized fecal microbiota transplantation transplantation on the treat of diarrhea-type irritable bowel syndrome.
To observe the similarities and differences of the effect between the two treatment methods on the disease.
and the changes in intestinal bacteria was also observed.
Studieoversikt
Status
Har ikke rekruttert ennå
Intervensjon / Behandling
Detaljert beskrivelse
In order to clarify the effectiveness of precision fecal bacteria transplantation, we have independently developed precision transplantation capsules.
Seventy patients with diarrhea-type irritable bowel syndrome were selected and randomly divided into 2 groups.
The patients in the first group were treated with standard fecal bacteria transplantation once, and the patients in other group were treated with precision transplantation capsules for 28 days.
The clinical symptoms of the patients of the two groups were observed before and 2, 4, 8, 12, 24, and 48 weeks after the treatment, and stool samples were collected for intestinal flora detection.
The purpose is to observe and compare the efficacy of the two treatment methods and their influence on the intestinal flora.
Studietype
Intervensjonell
Registrering (Forventet)
70
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Yanling Wei
- Telefonnummer: 15310354666
- E-post: lingzi016@126.com
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 75 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Male or female, aged 18 ~ 75 years.
- Patients who meet the diagnostic criteria of Rome IV of Irritable Bowel Syndrome and are definitely diagnosed as IBS-D.
- IBS has been diagnosed for more than 6 months, and has been treated with conventional drugs without obvious curative effect or repeated attacks.
- No other serious diseases, no mental disorders, and normal communication skills.
- Sign informed consent and agree to participate in this study.
- No antibiotics and probiotics were used within one month.
Exclusion Criteria:
- Patients are unwilling to participate in this study.
- Other serious diseases of heart, liver, kidney, respiration, digestion, blood and endocrine system.
- Combined with intestinal double infection, such as CDI, enterohemorrhagic Escherichia coli, Salmonella, Shigella, Campylobacter, plague, cytomegalovirus, etc.
- Liver function is significantly abnormal or has the following history of liver disease: AST or ALT is higher than 2 times of the upper limit of normal value, history of liver cirrhosis and hepatic encephalopathy, history of esophageal varices or history of portal shunt.
- There is evidence of renal function damage or the following history of kidney disease: serum creatinine is 1.5 times higher than the upper limit of normal value; History of dialysis; Or a history of nephrotic syndrome.
- Patients with various acute infections, tumors, severe arrhythmia, mental system disorders, and drug or alcohol addicts.
- History of abdominal surgery (except appendicitis, cholecystitis, caesarean section and hysterectomy).
- Those who were allergic to capsule drugs or contraindications.
- Lactose intolerance.
- Clinical researchers who are engaged in other related irritable bowel syndrome at the time of enrollment or within 3 months before enrollment.
- It is difficult to complete the follow-up, or various factors affecting the compliance.
- Pregnant or lactating women.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: FMT group
Standardized FMT once.Extract all the flora from the feces provided by the donor to make fecal bacteria transplant capsules.
The patient took orally on an empty stomach, each time using 3.2g of fecal bacteria.
|
The group includes 35 patients.
They will receive standardized FMT.
Fecal bacteria capsules are used for fecal bacteria transplantation, 16 capsules are used each time, each capsule contains 200mg of fecal bacteria, and it is used orally.
It was given only once.
|
|
Eksperimentell: JZ group
1.6g Po perday,for 28 days.
probiotics that are effective against diarrhea were selected to make precise flora capsules, which are taken when the patient is on an empty stomach, once a day, using 1.6 g of bacteria per day, orally for 28 consecutive days.
|
The group includes 35 patients.
They will receive Precision Flora Transplantation.
They were used self-developed precision transplant capsules for precision flora transplantation.
4 capsules are used each time.
Each capsule contains 400mg of various probiotics effective against diarrhea.
It is used orally, once a day,for 28 days.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
IBS-SSS score
Tidsramme: 12 Week after treatment
|
Severity of irritable bowel syndrome.The score varies from 0 to 500.
Higher scores suggest more severe condition.
|
12 Week after treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical remission rate
Tidsramme: 2、4、8、12 Week after treatment
|
Proportion of people in clinical remission after treatment
|
2、4、8、12 Week after treatment
|
|
GSRS score
Tidsramme: 0、2、4、8、12Week after treatment
|
Gastrointestinal Symptom Rating Scale.The score varies from 16 to 112.
Higher scores suggest more severe gastrointestinal pathology.
|
0、2、4、8、12Week after treatment
|
|
IBS-QoL score
Tidsramme: 0、2、4、8、12Week after treatment
|
Quality of life score for IBS patients.The score varies from 0 to 136.
Higher scores suggest greater impact of disease on life
|
0、2、4、8、12Week after treatment
|
|
PHQ-9
Tidsramme: 0、2、4、8、12Week after treatment
|
Patient Health Questionnaire-9.The score varies from 0 to 27.
Higher scores suggest more severe the depression
|
0、2、4、8、12Week after treatment
|
|
GAD-7
Tidsramme: 0、2、4、8、12Week after treatment
|
Generalized Anxiety Scale-7.The score varies from 0 to 21.
Higher scores suggest heavier the anxiety.
|
0、2、4、8、12Week after treatment
|
|
SAS
Tidsramme: 0、2、4、8、12Week after treatment
|
Self-rating Anxiety Scale.The score varies from 25 to 100.
Higher scores suggest greater degree of anxiety.
|
0、2、4、8、12Week after treatment
|
|
SDS
Tidsramme: 0、2、4、8、12after treatment
|
Self-rating Depression Scale.The score varies from 25 to 100.
Higher scores suggest more severe depression.
|
0、2、4、8、12after treatment
|
|
Intestinal flora
Tidsramme: 0、2、4、8、12Week after treatment
|
Use metagenomics technology to detect intestinal flora
|
0、2、4、8、12Week after treatment
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Yanling Wei, Army Medical Center of PLA
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Forventet)
20. mai 2021
Primær fullføring (Forventet)
1. oktober 2021
Studiet fullført (Forventet)
1. oktober 2022
Datoer for studieregistrering
Først innsendt
5. mai 2021
Først innsendt som oppfylte QC-kriteriene
17. mai 2021
Først lagt ut (Faktiske)
18. mai 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
18. mai 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
17. mai 2021
Sist bekreftet
1. mai 2021
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- TMMU-DP-GI-JZ-001
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .